Effect of Interleukin-28B Polymorphism on Interleukin-28 Expression and Immunological Recovery amongst HIV-1-Infected Individuals Following Antiretroviral Therapy

Srinidhi, B V; Fletcher, Gnanadurai John; Sachidanantham, Jaiprasath; Rupali, Priscilla; Ramalingam, Veena Vadhini; Demosthenes, John Paul; Abraham, O C; Pulimood, Susanne; Rebekah, Grace; Kannangai, Rajesh

doi:10.4103/ijmm.ijmm_17_299

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As in viral hepatitis, certain IFN-λ3/λ4 polymorphisms were associated with HIV resistance [42], while others increased susceptibility to acquired immunodeficiency syndrome-related Kaposi sarcoma [43]. Moreover, IFN-λ3 polymorphisms can influence both immunologic recovery and therapeutic response in HIV infection [44]. These observations provide evidence supporting the…”

Section: Human Immunodeficiency Virusmentioning

confidence: 70%

The Role of Type III Interferons in Human Disease

Malik

Issekutz

2021

CIM

View full text Add to dashboard Cite

Purpose: This literature review summarizes the main immunological characteristics of type III interferons (IFN) and highlights the clinically relevant aspects and future therapeutic perspectives for these inflammatory molecules. Source: Relevant articles in PubMed MEDLINE from the first publication (2003) until 2020. N=101 articles were included in this review. Principal findings: Type III IFNs represent a relatively newly described inflammatory cytokine family. Although they induce substantially similar signalling to the well-known type I IFNs, significant functional differences make these molecules remarkable. Type III IFNs have extensive biological effects, contributing to the pathogenesis of several diseases and also offering new diagnostic and therapeutic approaches: 1) their potent anti-viral properties make them promising therapeutics against viral hepatitis and even against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is causing the current coronavirus disease 2019 (COVID-19) pandemic; 2) imbalances in the IFN-λs contribute to several forms of chronic inflammation (e.g., systemic and organ-specific autoimmune diseases) and potentially predict disease progression and therapeutic response to biologic therapies; and 3) the antitumor properties of the type III IFNs open up new therapeutic perspectives against malignant diseases. Conclusion: Over the last 18 years, researchers have gathered extensive information about the presence and role of these versatile inflammatory cytokines in human diseases, but further research is needed to clarify the mechanistic background of those observations. Better understanding of their biological activities will permit us to use type III IFNs more efficiently in new diagnostic approaches and individualized therapies, consequently improving patient care.

show abstract

Section: Human Immunodeficiency Virusmentioning

confidence: 70%

The Role of Type III Interferons in Human Disease

Malik

Issekutz

2021

CIM

View full text Add to dashboard Cite

show abstract

“…included a very good size study population it was a heterogeneous cohort which is not ideal for genetic studies (14). In contrast, others have found the rs12979860 CC genotype to have a beneficial effect on HIV disease progression (15, 20). While Machmach et al found an over-representation of the rs12979860 CC genotype among HIV controllers compared to non-controllers (15), Srinidhi et al showed the CC genotype to be associated with increased CD4 T cell count following ART initiation (20).…”

Section: Discussionmentioning

confidence: 91%

Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs

Jõgeda

Avi

Pauskar

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

We investigated the presence of a single-nucleotide polymorphism designated rs12979860 in the interferon λ4 (IFNλ4) gene among 345 people who inject drugs (PWID) and 495 blood donors to evaluate associations between the rs12979860 genotypes and human immunodeficiency virus/hepatitis C virus (HIV/HCV). The rs12979860 TT genotype was over-represented among HIV+ PWID than HIV- PWID and blood donors (16% vs 8% and 10%, P = 0.03, respectively). PWID with TT genotype had approximately twice the probability of being HIV+ (odds ratio [OR], 2.19; 95% confidence interval [CI], 1.11 to 4.33) than PWID without TT. Every additional year of intravenous drug use (IVDU) decreased the OR 1.16 times (OR, 0.86; 95% CI, 0.75 to 0.98). This suggests that rs12979860 TT increases susceptibility to HIV and this impact decreases with increasing duration of IVDU.

show abstract

“…По данным W. Hou и соавт., ИЛ-28В способен влиять на ВИЧ путем ингибирования репликации посредством внутриклеточных и внеклеточных механизмов [10]. Результаты исследований последних лет поддерживают теорию о контроле обеих инфекций с участием ИЛ-28В [11], а также указывают на связь между полиморфизмом гена ИЛ-28В и иммунологическим ответом у ВИЧ-инфицированных пациентов на антиретровирусной терапии (АРВТ) [12].…”

unclassified

Сatamnestic data on the effect of interferon therapy on the course of combined HIV/HCV-infection

Фазылов¹,

Манапова²,

Акифьев³

2021

VIČ-infekc. immunosupr.

View full text Add to dashboard Cite

Aim: catamnestic analysis of the effectiveness of antiviral therapy for chronic hepatitis C in combination with HIV infection.Materials and methods. A retrospective study included 145 patients with combined HCV/HIV infection for 8±0,43 years.Results. 55% of patients received antiviral therapy for chronic hepatitis with pegylated interferons and ribavirin. The frequency of achieving a stable virological response is 73%. Persistent virological response with favorable Il-28B genotypes was detected in 85% of cases, with unfavorable genotypes less frequently — in 63% (p=0,028); the relapse rate is 27%. The level of HIV RNA viral load and the frequency of patients with secondary diseases was higher in patients with natural HCV/HIV infection with favorable interleukin-28B genotypes compared to other comparison groups (р<0,05).Conclusion. The course of chronic hepatitis C after therapy was more positive with favorable Il-28B genotypes. HIV infection was more severe in the absence of antiviral therapy for chronic hepatitis C.

show abstract

Effect of Interleukin-28B Polymorphism on Interleukin-28 Expression and Immunological Recovery amongst HIV-1-Infected Individuals Following Antiretroviral Therapy

Abstract: Our preliminary findings suggest that IL-28 polymorphisms could influence both immunological recovery and therapeutic response in HIV infection. Hence, functional studies are warranted to understand the mechanistic basis of IL-28-mediated host genetic influence on HIV therapeutic response.

Cited by 3 publications

References 24 publications

The Role of Type III Interferons in Human Disease

The Role of Type III Interferons in Human Disease

Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs

Сatamnestic data on the effect of interferon therapy on the course of combined HIV/HCV-infection

Contact Info

Product

Resources

About